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Background: The relationship between TB/HIV co-infection and common mental disorders (CMD) is not well
investigated. A follow up study was conducted to assess the change in CMD over a 6-months period and its
predictors among TB/HIV co-infected and HIV patients without TB in Ethiopia.
Methods: A longitudinal study was conducted in 2009. A total of 465 HIV/AIDS patients without TB and 124 TB/HIV
co-infected patients from four antiretroviral treatment (ART) centers in Ethiopia were recruited to assess CMD and
quality of life (QoL). CMD and QoL were assessed at baseline and at six month using the Kessler-10 scale and the
short Amharic version of the World Health Organization Quality of Life Instrument for HIV clients (WHOQOL HIV-Bref)
respectively. Multivariate analysis was conducted using generalized estimating equations (GEE) using STATA to assess
change in CMD and its predictors.
Results: At the 6 month, 540 (97 TB/HIV co-infected and 455 HIV/AIDS patients without TB) patients completed the
follow up and 8.6% (21% among TB/HIV co-infected and 2.2% among HIV patients without TB) lost to follow-up.
At baseline, 54.4% of TB/HIV co-infected patients had mild to severe mental disorder compared to 41.2% among HIV
patients without TB. At the six month follow up, 18.1% of TB/HIV co-infected patients had mild to severe mental
disorder compared to 21.8% among HIV patients without TB. The decline of the prevalence of any form of metal
disorder was 36.3% among TB/HIV co-infected patients compared to 19.4% among HIV patients without TB (P<0.001).
QoL was strongly associated with CMD in TB/HIV co-infected patients and HIV patients without TB (β = −0.04, P<0.001)
after controlling the effect of several confounding variables such as sex, income, WHO disease stage, duration on ART,
CD4 lymphocyte count, adherence to ART and social support.
Conclusion: The prevalence of CMD has significantly reduced particularly among TB/HIV co-infected patients over
a 6 months period. Poor QoL is the major independent predictors of CMD. We recommend integration of mental
health services in TB/HIV programs. Training of health care providers at TB/HIV clinics could help to screen and
treat CMD among TB/HIV co-infected patients.
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Neuropsychiatric conditions represent 13% of the total
disease burden and it is the third largest cause of disability-
adjusted life years lost (DALYs) after infectious and para-
sitic diseases (41%) and cardiovascular diseases (26%) [1].
The importance of mental health is estimated to in-
crease in the next two decades. Mental health conditions
such as depression are projected to become the leading
burden of DALYs by the year 2030 [2,3]. Three-quarters
of this burden occurs in the developing world where
Tuberculosis and HIV are prevalent [2,3].
Tuberculosis (TB) and HIV co-infection comprises an
enormous burden on individuals and health care systems
particularly in resource constrained countries [4,5]. Re-
cently, co-morbidities between mental health and infectious
diseases and integration of these diseases in the primary
health care are getting much attention. Few studies have
documented the interaction between HIV/AIDS and men-
tal health problems. The presence of mental disorder, par-
ticularly depression, predisposes individuals to unprotected
sexual behavioral and drug abuse which are the major risk
factors for HIV/AIDS infection [6]. On the other hand,
HIV/AIDS infection causes psychological trauma and
affect the nervous system directly resulting in depres-
sion, mania and other cognitive disorders [7-11]. Op-
portunistic infections as a result of HIV/AIDS [6] and
anti-retroviral drugs particularly efavirenz can also cause
mental health disorders [6].
Few studies have documented high prevalence of tuber-
culosis among individuals with mental health problems
[12,13]. In addition, high prevalence of depression was
recorded among tuberculosis patients compared to health
controls [14,15].
The complex interaction among TB, HIV and mental
disorders could affect the quality of life (QoL) of individuals
[4,16,17]. Since the advent of ART, the incidence of HIV-
associated dementia has halved [18] and the prevalence
of opportunistic infection of the central nervous system
decreased [18,19]. However, there are reports indicating
rise in the incidence of HIV encephalopathy [19].
There is a dearth of literature on the mental health status
of TB/HIV co-infected patients over time. We conducted a
follow up study in Ethiopia to document the changes in
prevalence of CMD and its predictors among TB/HIV-
co-infected and HIV patients without TB over six months
period.
Methods
Study settings and population
This is a longitudinal study with 6 month follow-up period.
The baseline survey was conducted from February to April,
2009 to assess the prevalence of CMD among 465 HIV/
AIDS patients without TB and 124 TB/HIV co-infected pa-
tients from the ART clinics of Adama, Nekemet and Jimmaspecialized hospitals in Ethiopia. The methodology and
the baseline findings are published in a previous article
[16]. In general, 465 patients without TB and 124 TB/HIV
co-infected patients who were taking ART were recruited
in the three hospitals to compare CMD among the two
groups. The sample size was determined based on the
following assumptions: 5% lower mean score of physical
QoL life among TB/HIV co-infected patients compared
to HIV patients without TB, 95%CI, a 1:3 ratio of HIV/TB
co-infected patients versus HIV patients, and a 10% for
non-response rate. All the TB/HIV co-infected patients
were in the intensive phase of anti-TB treatment during
the recruitment period. For each TB/HIV co-infected pa-
tients, 3 HIV patients without active TB were selected in
the TB/HIV clinics using a simple random sampling
technique. The exclusion criteria for both groups were
age less than 15 years, the presence of an opportunistic
infection or a known chronic illness like diabetes mellitus
and hypertension.Data collection procedures and follow up
Diagnoses of TB and HIV at baseline were based on the
national guideline [20]. Smear microscopy was the major
diagnostic tool for pulmonary TB. TB lymphadenitis was
diagnosed based on clinical parameters and cytological
examination obtained by fine needle aspiration. TB was
excluded from the HIV patients by a thorough symptom
screening.
After recruitment, patients were appointed monthly to
the ART clinics of the respective hospitals to take their
medication (anti-retroviral and ant-TB drugs). During each
visit, patients were thoroughly assessed by trained nurses
for drug side effects, general health status and presence
of symptoms of opportunistic infection including TB.
CD4 lymphocyte count and WHO clinical staging were
extracted from the patients’ record at baseline and at the
6th month. CMD and QoL were measured at baseline and
at the 6th month of follow up.
Common Mental Disorder was measured using the
Kessler 10 scales [21]. The Kessler-10 scales is validated
in Ethiopia against psychiatrists’ diagnosis using the
comprehensive psychopathological scale [22,23] and it
contains 10 questions each containing 5-point Likert
scales (1 = never, 2 = a small part of the time, 3 = some
of the time, 4 = most of the times, 5 = all of the time).
The K-10 instrument is a useful screening tool to identify
CMD such as depression, anxiety and somatoform disor-
ders. It asks questions regarding the presence of depres-
sion, tiredness, nervousness, restlessness, hopelessness,
and worthlessness in 30 days prior to the survey. To
assess the degree of mental health status of individuals,
CMD was categorized as normal (score <20), moderate
(score 20-24), and severe (score above 25) based on the
Table 1 Socio-demographic characteristics of participants




Age in years, Mean (SD) 34.5 (9.5) 33.4 (8.1) 0.227
Sex
Male 43 185 0.505
Female 54 270
Employment
Unemployed 7 52 0.223
Employed 90 403
WHO staging
Stage I 0 71 0.000
Stage II 0 64
Stage III 79 216
Stage IV 18 65
CD4 lymphocyte count,
(medina)
392.6 (375.0) 383.7 (358.0) 0.762
At least missed one doses
of Anti-TB or ART
7(7.1%) 10(1.8%) -
Lost to follow-up 27 10 0.000
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have used cut off score 20 to identify cases CMD [24,25].
QoL was measured through face to face interview
using the short Amharic version of the World Health
Organization Quality of Life Instrument for HIV clients
(WHOQOL HIV-Bref) [26]. The QoL instrument is pub-
lished in the previous article [16]. In brief, it consisted of
31 Likert scale questions in six domains of QoL: Physical
health (4 items); psychological well being (5 items); social
relationship (4 items); environmental health (8 items);
level of independence (4 items) and spiritual health (4
items). There were two general questions about general
QoL and perceived general health. The overall quality of
life was measured using all the questions as described in
elsewhere [26].
Data analysis
Data were analyzed using the SPSS version 16.0 and
STATAW version 11 software. Items score of the K-10
were summed to create a continuous CMD outcome vari-
able. Similarly, items scores of the WHOQOL-HIV-Bref
instrument was summed to create a continuous QoL ex-
posure variable. We used t-test and F-test to compare
means of CMD between groups.
Paired-T-tests were used to compare repeated measure-
ments of CMD at baseline and six months. Multivariate
analysis was conducted using generalized estimating equa-
tions (GEE) using the Gaussian family and the identity
link function. In this model, the correlations between
the baseline and 6-month measurements are taken into
account. Variables with significant correlation were re-
moved. A P-value of less or equal to 0.05 was taken as
the cut-off value for significance.
Ethical considerations
Ethical clearance was obtained from the Jimma University
ethical review board. Written informed consent was ob-
tained from the study participants. To ensure confiden-
tiality, we used codes to analyze the data. Patients who
scored above 20 on the Kessler scale were referred to
Psychiatry units in each hospital for further diagnosis
and management.
Results
At baseline, 465 HIV patients without TB and 124 TB/HIV
co-infected patients were included. Of the co-infected
patients, smear negative, smear positive and extra pulmon-
ary TB accounted for 61 (49.2%), 42 (33.9%), 21 (16.9%) re-
spectively. At 6 month, 540 (97 TB/HIV co infected and
455 HIV patients without TB) patients completed the
follow up and 8.6% lost to follow-up. Over the six months
period, 5/443(1.12%) HIV/AIDS patients developed active
pulmonary TB. During the follow up period, 7.1% of the
TB/HIV co-infected patient discontinued their anti-TBtreatment at least once and 10 (1.8%) patients with HIV/
AIDS missed at least one dose of ART (Table 1).
Common mental disorders at baseline and 6-months
At baseline, 24.8% and 15.2% of the TB/HIV co-infected
patients had severe and moderate form of CMD respect-
ively. On the other hand, the prevalence of severe form
of CMD among HIV/AIDS patients without TB at base-
line and 6 month was 8.6% and 3.8% respectively. At the
six month, the prevalence of severe form of CMD among
TB/HIV-co-infected patients was 1.9% which showed a
difference of 22.9 percentage-points. Any form of men-
tal disorder had decreased by 36.3 percentage points in
TB/HIV co-infected patients at six month compared to
the baseline. Any form of CMD among HIV/AIDS pa-
tients without TB was reduced by 19.4 percentage points
at the six month (Table 2).
Predictors of common mental disorders
QoL was strongly associated with CMD in TB/HIV co-
infected patients and HIV/AIDS patients without TB (β =
−0.04, P<0.001) after controlling the effect of several
confounding variables such as sex, income, CD4 lympho-
cyte count, adherence to ART and social support (Table 3).
A ROC curve exploring the best cut-off points of
physical and psychological quality of life as predictors of
CMD showed that QoL is the best predictors of CMD
with area under the curve of 0.82. A cut off point of 11.5
for physical and 14.0 for psychological dimension of QoL
gave 80% sensitivity (Figure 1).
Table 2 Change in common mental disorders over 6 months follow-up among participants



















Well 45.6 81.9 36.3 0.000 58.8 78.2 19.4 0.000
Mild disorder 14.4 9.5 −4.9 17.7 14.8 −2.9
Moderate mental disorder 15.2 6.7 −8.5 14.9 3.1 −11.8
Severe mental disorder 24.8 1.9 −22.9 8.6 3.8 −4.8
Any mental disorder 54.4 18.1 −36.3 41.2 21.8 −19.4
Table 3 Predictors of CMD among TB/HIV co-infected and
HIV/AIDS patients without TB, Ethiopia
TB/HIV co-infected HIV infected
Variables Β (SE) P-value Β (SE) P-value
Sex
Male 1.00 1.00
Female −0.14 (0.3) 0.647 −0.03 (0.2) 0.826
Literacy status
Illiterate 1.00 1.00
Literate −0.10 (0.4) 0.801 0.21 (0.2) 0.289
Baseline CD4 count
<200 1.00 1.00
>200 0.57 (0.3) 0.097 −0.20 (0.2) 0.198
WHO staging
I NA 1.00
II NA 0.21 (0.2) 0.406
III 1.00 0.04 (0.2) 0.841
VI 0.3 (0.3) 0.405 −0.08 (0.2) 0.749
Duration on ART 0.03 (0.03) 0.130 −0.003 (0.0) 0.587
Adherence to ART
Yes 1.00 1.00
No −0.71 (0.6) 0.268 −0.08 (0.4) 0.840
Adherence to anti-TB
Yes 1.00 NA
No −0.37 (0.9) 0.683
Social support
Yes 1.00 1.00
No −0.25 (0.4) 0.501 −0.14 (0.2) 0.481
Source of income
Yes 1.00 1.00
No −0.11 (0.4) 0.795 0.01 (0.2) 0.967
QoL (WHO-QoL) −0.04 (0.01) 0.000 −0.04 (0.0) 0.000
Employment
Employed 1.00 1.00
Unemployed 0.28 (0.6) 0.619 −0.37 (0.2) 0.118
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This is the first follow up study to evaluate the change
in CMD among TB/HIV co-infected and HIV patients
without TB who are on ART in Ethiopia. This study re-
veals that there is significant decline in the prevalence of
CMD particularly among TB/HIV co-infected patients
over a six month period. The change in CMD prevalence
among TB/HIV co-infected individuals is twice than that
of HIV patients without TB. Among several exposure
variables, QoL is the best predictors of CMD both in co-
infected patients and HIV/AIDS patients without TB.
This study reveals that the prevalence of CMD among
TB/HIV co-infected and HIV patients without TB is very
high. Other literatures have also documented high preva-
lence of mental health problems among people with HIV/
AIDS [8,9] and patients with tuberculosis [12,13]. In the
present study, the decline in prevalence of CMD at the
6 month of treatment and follow up was more marked
among TB/HIV patients compare to people living with
HIV without TB. This could be explained by two major
reasons. First, in the continuation phase of anti-TB treat-
ment (2-8 months), the physical and functional status of
the patients could improve significantly which in turn
brings improved mental health status of individuals.
Second, perceived stigma associated with TB might also
be reduced at 6 months of anti-TB treatment. Reduction
in stigma might have major effect on the mental status
of patients. Previous study has proven that presence of
perceived stigma is highly associated with depression
[16,27]. A study in Uganda has also reveals that quality
of life and mental health status has improved at 12-
monhts of ART [28]. In our study, continues counseling
and health education given by the health care providers
about adherence, diets, and self-care and prevention of
opportunistic infections might contribute for the reduc-
tion of CMD in both group of patients.
In our study, QoL was the best predictor of CMD; how-
ever, CMD could also cause poorer QoL among patients
with TB/HIV disease. In this study, we could not establish
the temporal relationship of the two conditions. Litera-
tures on the relationship between QoL and mental dis-
orders are lacking worldwide. A well designed cohort or
Figure 1 ROC curve exploring QoL change of cut off point for predicting CMD among TB/HIV co-infected and HIV patients without TB,
Ethiopia (area under the curve; physical=0.818 and psychological QoL=0.821; both areas are statistically significantly from an areas of 0.5).
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relationship between mental disorders and QoL.
Despite significant reduction in CMD at the 6-months
of follow up, CMD is still a major co-morbidity of TB/HIV
disease. In a country such as Ethiopia where mental health
is not an integral part of HIV/AIDS or TB care and treat-
ment services, CMD would have negative impact on the
treatment outcome of patients [6]. Mental disorders such
as depression might also have negative impact on immune
status of patients which counteract the benefit of ART [6].
Limitations of the study
This study is the first of its kind to evaluate the trends
in CMD among TB/HIV co-infected patients. The sample
size is adequate to measure the change and the effect size.
However, the follow up period is too short to analyze mul-
tiple confounders using survival analysis and Cox regres-
sion. Loss to follow up of more TB/HIV co-infected patients
compared to HIV/AIDS patients without TB could also
introduced bias. However, the loss to follow up group is
not significantly different from the other group except in
the WHO clinical stage. Most of the lost to follow-up
were in WHO stage 3 and 4 (P=0.002).
Conclusions and recommendations
The prevalence of CMD has significantly reduced particu-
larly among TB/HIV co-infected patients over a 6 months
period. However, CMD is still a major co-morbidity ofTB/HIV disease. Poor QoL is the major independent
predictors of CMD.
Based on the findings of this study, we recommend the
integration of mental health services in TB/HIV programs.
Training of health care providers at TB/HIV clinics could
be helpful to screen and treat CMD among TB/HIV co-
infected patients.
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